EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery

Ying-Qi Lin, Ke-Ke Feng, Jie-Ying Lu, Jing-Qing Le, Wu-Lin Li, Bing-Chen Zhang, Cheng-Lei Li, Xun-Huan Song, Ling-Wu Tong, Jing-Wei Shao

Journal of Controlled Release · 2023-09 · 361 · 727-749

DOI: 10.1016/j.jconrel.2023.08.028 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023-09. Verfasst von Ying-Qi Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 151 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR/Cas9 genome editing is a promising therapeutic technique, which makes precise and rapid gene editing technology possible on account of its high sensitivity and efficiency. CRISPR/Cas9 system has been proved to able to effectively disrupt and modify genes, which shows great potential for cancer treatment. Current researches proves that virus vectors are capable of effectively delivering the CRISPR/Cas9 system, but immunogenicity and carcinogenicity caused by virus transmission still trigger serious consequences. Therefore, the greatest challenge of CRISPR/Cas9 for cancer therapy lies on how to deliver it to the target tumor site safely and effectively. Non-viral delivery systems with specific targeting, high loading capacity, and low immune toxicity are more suitable than viral vectors, which limited by uncontrollable side effects. Their medical advances and applications have been widely concerned. Herein, we present the molecule mechanism and different construction strategies of CRISPR/Cas9 system for editing genes at the beginning of this research. Subsequently, several common CRISPR/Cas9 non-viral deliveries for cancer treatment are introduced. Lastly, based on the main factors limiting the delivery efficiency of non-viral vectors proposed in the existing researches and literature, we summarize and discuss the main methods to solve these limitations in the existing tumor treatment system, aiming to introduce further optimization and innovation of the CRISPR/Cas9 non-viral delivery system suitable for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeoplasmsGene EditingTechnology

Stichwörter der Autor:innen

CRISPR/Cas9Non-viral vectorscancer therapyediting efficient

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, China.
  • Faculty of Foreign Studies, Guangdong Baiyun University, Guangzhou 510450, China.
  • Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, China. Electronic address: shaojingwei@fzu.edu.cn.

Zitieren

APA

Lin, Y. Q., Feng, K. K., Lu, J. Y., Le, J. Q., Li, W. L., Zhang, B. C., Li, C. L., Song, X. H., Tong, L. W., & Shao, J. W. (2023). CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery. Journal of Controlled Release, 361, 727-749. https://doi.org/10.1016/j.jconrel.2023.08.028

Vancouver

Lin YQ, Feng KK, Lu JY, Le JQ, Li WL, Zhang BC, et al. CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery. Journal of Controlled Release. 2023;361:727-749. doi:10.1016/j.jconrel.2023.08.028

BibTeX
@article{Lin2023,
  author = {Lin, Ying-Qi and Feng, Ke-Ke and Lu, Jie-Ying and Le, Jing-Qing and Li, Wu-Lin and Zhang, Bing-Chen and Li, Cheng-Lei and Song, Xun-Huan and Tong, Ling-Wu and Shao, Jing-Wei},
  title = {CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {361},
  pages = {727--749},
  doi = {10.1016/j.jconrel.2023.08.028}
}
Kostenlos starten →